Artemisinin (Sesquiterpene Lactone)

Artemisinin is a sesquiterpene lactone derived from Artemisia annua that disrupts cellular iron homeostasis and generates reactive oxygen species. It demonstrates potent antimalarial activity and shows promising anti-cancer properties through targeted cell death mechanisms.

Origin & History

Artemisinin is a sesquiterpene lactone isolated from the leaves of sweet wormwood (*Artemisia annua*), an herb native to temperate China used in traditional Chinese medicine. First extracted in the 1970s through a Chinese government antimalarial project, it is typically obtained through solvent-based extraction methods using ethanol or petroleum ether from dried leaves.

Historical & Cultural Context

Artemisinin derives from *Artemisia annua*, used in Traditional Chinese Medicine for over 2,000 years to treat fevers including malaria-like 'intermittent fever.' Historical texts like 'Zhou Hou Bei Ji Fang' (340 AD) describe hot-water extraction methods for treating chills and fevers.

Health Benefits

• Malaria treatment: Phase III RCT showed 98% efficacy with artemisinin-based combination therapies vs. 48% for standard treatment (PMID: 32171078)
• Cancer therapy support: Phase I trials demonstrated safety at 200mg/day oral dose with anti-proliferative effects in breast and colorectal cancer
• Anti-inflammatory effects: RCT-equivalent studies showed non-inferiority to hydroxychloroquine for rheumatoid arthritis
• Lupus nephritis management: Clinical evidence supports effectiveness for recurrence inhibition
• COVID-19 symptom duration: Prospective study showed shortened treatment time

How It Works

Artemisinin contains an endoperoxide bridge that reacts with intracellular iron, particularly heme iron in malaria parasites, generating cytotoxic free radicals and alkylating proteins. The compound disrupts mitochondrial function and triggers apoptosis through oxidative stress pathways. In cancer cells, artemisinin exploits elevated iron levels to selectively induce cell death while sparing healthy cells.

Scientific Research

Large-scale phase III RCTs (n=1100) across Southeast Asia demonstrated artemisinin-based combination therapies achieved 98% cure rates for drug-resistant malaria (PMID: 32171078). Meta-analyses of 5 RCTs (n=772) confirmed comparable efficacy to other antimalarial combinations (PMID: 33013398), while phase I cancer trials established safety profiles for oral (200mg/day) and IV (18mg/kg) formulations.

Clinical Summary

Phase III randomized controlled trials involving over 1,400 patients showed artemisinin-based combination therapies achieved 98% cure rates for uncomplicated malaria versus 48% for conventional treatments. Phase I cancer studies with 24-36 participants demonstrated safety at oral doses up to 200mg daily, with preliminary anti-proliferative effects observed in breast and colorectal cancer patients. Multiple systematic reviews confirm artemisinin's superiority over chloroquine and other antimalarials, though cancer research remains in early-stage clinical development. Current evidence strongly supports antimalarial use but cancer applications require larger controlled trials.

Nutritional Profile

Artemisinin is a purified bioactive sesquiterpene lactone compound, not a whole food or nutritional ingredient; it contains no meaningful macronutrients (carbohydrates, fats, proteins), dietary fiber, vitamins, or minerals in pharmacologically relevant doses. Key bioactive compound: Artemisinin (C15H22O5, MW 282.33 g/mol) — the defining constituent, characterized by an endoperoxide bridge (1,2,4-trioxane ring) essential for biological activity. Typical therapeutic doses range from 200–500 mg/day in clinical settings. Bioavailability: Oral bioavailability is approximately 32% due to extensive first-pass hepatic metabolism; peak plasma concentration (Cmax) reached within 1–2 hours post-ingestion. Half-life: approximately 2–3 hours. The compound undergoes auto-induction of CYP2B6 and CYP3A4 enzymes, reducing plasma levels with repeated dosing by up to 50–70% after 5–7 days. Semi-synthetic derivatives (artesunate, artemether, dihydroartemisinin) exhibit improved bioavailability of 80–90%. No clinically significant micronutrient content. Fat-soluble properties enhance absorption when taken with lipid-containing food, increasing AUC by approximately 30%. Concentrated plant-source (Artemisia annua) aerial parts contain approximately 0.01–0.8% artemisinin by dry weight, alongside minor flavonoids (artemetin, casticin) and essential oils, but isolated pharmaceutical-grade artemisinin is a single purified compound.

Preparation & Dosage

Clinically studied doses: Oral artemisinin 200mg/day for cancer; IV artesunate up to 18mg/kg MTD; standard ACT regimens for malaria vary by specific derivative. Artemether predicted at 240mg for therapeutic plasma levels. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Piperaquine, mefloquine, iron supplements, vitamin C, curcumin

Safety & Interactions

Common side effects include nausea, vomiting, and dizziness, occurring in 10-15% of patients at therapeutic doses. Artemisinin may interact with CYP2B6 and CYP3A4 enzymes, potentially affecting metabolism of warfarin, rifampin, and certain antiretrovirals. The compound is contraindicated during first trimester pregnancy due to potential embryotoxicity, though WHO considers it safe after 13 weeks gestation. Patients with severe hepatic impairment should use caution as artemisinin undergoes extensive liver metabolism.